For systolic blood pressure we did not perform a meta-analysis due to significant heterogeneity. Two trials examined the effect of CoQ10 on blood pressure. None of the included studies provided data on adverse events. No studies reported mortality or non-fatal cardiovascular events. The dose of CoQ10 varied between 100 mg/day and 200 mg/day and the duration of the interventions was similar at around three months. All six trials were small-scale, recruiting between 20 and 52 participants one trial was at high risk of bias for incomplete outcome data and one for selective reporting all studies were unclear in the method of allocation and therefore for selection bias. All trials were conducted in participants at high risk of CVD, two trials examined CoQ10 supplementation alone and four examined CoQ10 supplementation in patients on statin therapy we analysed these separately. We identified six RCTs with a total of 218 participants randomised, one trial awaiting classification and five ongoing trials. More longer-term trials are needed to determine the effect of CoQ10 on cardiovascular events. We also identified five ongoing trials and the results from these will add to the evidence base in due course. Very few small trials contributed to the analyses and no conclusions can be drawn at this time. The trials were small and short-term, none measured cardiovascular events or adverse events, and we regarded two of the six trials as being at high risk of bias. Two examined CoQ10 supplementation alone and four examined CoQ10 supplementation in patients on statin therapy. All were conducted in participants at high risk of CVD. We found six completed randomised controlled trials with a total of 218 participants randomised. We included trials administering CoQ10 as a single supplement in healthy adults or those at high risk of CVD (but without a diagnosis of CVD) and measuring cardiovascular events or major CVD risk factors, such as blood pressure and lipid levels. This review therefore assessed the effectiveness of CoQ10 supplementation for CVD prevention. Deficiencies in CoQ10 have been associated with CVD. One such supplement is coenzyme Q10 (CoQ10), which is an antioxidant. Dietary supplements have received a great deal of attention for the prevention of CVD. However, it is thought that CVD risk can be lowered by changing a number of modifiable risk factors, such as diet. Cardiovascular disease (CVD) is the result of complications of the heart and blood vessels and is a worldwide healthcare burden.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |